within Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AG01_ValproicAcid;

model ValproicAcid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 1,
    Cl = 1.9444444444444445e-07,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.00015,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0038333333333333336,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>ValproicAcid</td></tr><tr><td>ATC code:</td><td>N03AG01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.15</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.01</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Valproic acid is an antiepileptic drug (AED) used primarily for the treatment of epilepsy, bipolar disorder, and prevention of migraine headaches. It is a broad-spectrum anticonvulsant approved for use in many countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters observed in healthy adult volunteers aged 18-55, both male and female, following a single oral dose.</p><h4>References</h4><ol><li><p>Wang, WJ, et al., &amp; Chen, F (2024). Population pharmacokinetics of valproic acid in children with epilepsy: Implications for dose tailoring when switching from oral syrup to sustained-release tablets. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 13(9) 1554–1569. DOI:<a href=\"https://doi.org/10.1002/psp4.13191\">10.1002/psp4.13191</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38923247/\">https://pubmed.ncbi.nlm.nih.gov/38923247</a></p></li><li><p>Xu, S, et al., &amp; Zhao, L (2018). Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 122 170–178. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2018.06.033\">10.1016/j.ejps.2018.06.033</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29981400/\">https://pubmed.ncbi.nlm.nih.gov/29981400</a></p></li><li><p>Xu, S, et al., &amp; Zhao, L (2018). Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. <i>European journal of clinical pharmacology</i> 74(5) 583–591. DOI:<a href=\"https://doi.org/10.1007/s00228-018-2414-8\">10.1007/s00228-018-2414-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29340733/\">https://pubmed.ncbi.nlm.nih.gov/29340733</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N03AG01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end ValproicAcid;
